Corbus Pharmaceuticals Holdings Inc


Cantor Weighs in on Corbus Pharmaceuticals Holdings Inc (CRBP) as Resunab Clinically Validated in Scleroderma

Cantor analyst Elemer Piros reiterated a Buy rating on shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) with a price target of $17, after the …

Stock Update (NASDAQ:CRBP): Here’s Why Corbus Pharmaceuticals Holdings Inc Shares Jumped 65%

Investors in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) should be smiling from ear to ear today after the drug maker announced positive topline results …

Stock Update (NASDAQ:CRBP): Here’s Why Corbus Pharmaceuticals Holdings Inc Shares Are Falling 25% Today

For those wondering why Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) shares are presently taking a 25% nosedive, look no further than The Street blogger …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts